Dysregulated lipid metabolism is a core hallmark of diffuse large B-cell lymphoma (DLBCL), while the upstream non-coding RNA regulatory network targeting sphingosine kinase 1 (SPHK1), a key lipogenic kinase, remains largely uncharacterized in DLBCL. Here, we identified and validated a novel ceRNA regulatory axis consisting of circ_0006523, miR-659-3p, and SPHK1 in DLBCL clinical tissues and cell lines. circ_0006523 and SPHK1 were significantly upregulated, whereas miR-659-3p was downregulated, in DLBCL tissues and cell lines; high circ_0006523 expression was associated with advanced Ann Arbor stages (Ⅲ–IV). Mechanistically, RNase R-resistant circ_0006523 acted as a competing endogenous RNA (ceRNA) to sponge miR-659-3p, thus relieving its repression on SPHK1. Functionally, circ_0006523 promoted DLBCL cell proliferation and elevated intracellular lipid abundance via the miR-659-3p/SPHK1 axis. Collectively, the circ_0006523/miR-659-3p/SPHK1 axis modulates DLBCL proliferative phenotypes in vitro. Circ_0006523 expression correlates with advanced Ann Arbor stage in a limited DLBCL cohort, and this axis may provide preliminary molecular insights for further investigation in DLBCL.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: